Cover Image
市場調查報告書

胰臟炎:開發中產品分析

Pancreatitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246013
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
胰臟炎:開發中產品分析 Pancreatitis - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 76 Pages
簡介

胰臟炎是指胰臟發炎,症狀是上腹部痛、噁心、嘔吐、碰觸腹部會有壓痛,以及體重減輕等。發病的要因有酒精成癮、吸煙、胰臟炎的家族病史、感染症、腹部受傷及胰臟癌等。治療方法為抗生素及緩和痛覺用的藥物療法。

本報告提供胰臟炎治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

胰臟炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

胰臟炎:企業開發中的治療藥

胰臟炎:大學/機關研究中的治療藥

胰臟炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

胰臟炎:企業開發中的產品

胰臟炎:大學/機關研究中的產品

胰臟炎的治療藥開發企業

  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Bharat Serums And Vaccines Limited
  • CalciMedica, Inc.
  • Dynavax Technologies Corporation
  • Generon (Shanghai) Corporation Ltd.
  • GlaxoSmithKline Plc
  • Pharming Group N.V.

胰臟炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

胰臟炎:最近的開發平台趨勢

胰臟炎:暫停中的計劃

胰臟炎:中止開發的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8478IDB

Summary

Global Markets Direct's, 'Pancreatitis - Pipeline Review, H2 2016', provides an overview of the Pancreatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatitis
  • The report reviews pipeline therapeutics for Pancreatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pancreatitis therapeutics and enlists all their major and minor projects
  • The report assesses Pancreatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pancreatitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pancreatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pancreatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pancreatitis Overview
  • Therapeutics Development
    • Pipeline Products for Pancreatitis - Overview
    • Pipeline Products for Pancreatitis - Comparative Analysis
  • Pancreatitis - Therapeutics under Development by Companies
  • Pancreatitis - Therapeutics under Investigation by Universities/Institutes
  • Pancreatitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Pancreatitis - Products under Development by Companies
  • Pancreatitis - Products under Investigation by Universities/Institutes
  • Pancreatitis - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp.
    • Atox Bio Ltd.
    • Bharat Serums And Vaccines Limited
    • CalciMedica, Inc.
    • Dynavax Technologies Corporation
    • Generon (Shanghai) Corporation Ltd.
    • GlaxoSmithKline Plc
    • LipimetiX Development Inc
    • Novartis AG
    • Pharming Group N.V.
    • Sun BioPharma, Inc.
  • Pancreatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DV-1179 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-637 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-180 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2795039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-6288B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-2pal18S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PZ-235 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulinastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Withaferin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pancreatitis - Dormant Projects
  • Pancreatitis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pancreatitis, H2 2016
  • Number of Products under Development for Pancreatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pancreatitis - Pipeline by Angion Biomedica Corp., H2 2016
  • Pancreatitis - Pipeline by Atox Bio Ltd., H2 2016
  • Pancreatitis - Pipeline by Bharat Serums And Vaccines Limited, H2 2016
  • Pancreatitis - Pipeline by CalciMedica, Inc., H2 2016
  • Pancreatitis - Pipeline by Dynavax Technologies Corporation, H2 2016
  • Pancreatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
  • Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2016
  • Pancreatitis - Pipeline by Novartis AG, H2 2016
  • Pancreatitis - Pipeline by Pharming Group N.V., H2 2016
  • Pancreatitis - Pipeline by Sun BioPharma, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pancreatitis - Dormant Projects, H2 2016
  • Pancreatitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pancreatitis, H2 2016
  • Number of Products under Development for Pancreatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top